LEXINGTON, Mass.--(BUSINESS WIRE)--Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that it has launched an initial public offering of 7,700,000 shares of its common stock. In addition, Translate Bio expects to grant the underwriters a 30-day option to purchase up to 1,155,000 additional shares of common stock at the public offering price, less the underwriting discount. All of the shares to be sold in the proposed offering will be offered by Translate Bio. The initial public offering price is expected to be between $12.00 and $14.00 per share. Translate Bio has applied to list the shares on the Nasdaq Global Market under the symbol “TBIO.”
Citigroup, Leerink Partners and Evercore ISI are acting as joint book-running managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
A registration statement relating to the offering has been filed with the Securities and Exchange Commission but has not yet become effective. The securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective.
The proposed offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus may be obtained by contacting Citigroup Global Markets Inc. c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at 1-800-831-9146; Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6132, or by email at syndicate@leerink.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, New York 10055, by telephone at 888-474-0200, or by email at ecm.prospectus@evercore.com. The registration statement may be obtained free of charge at the SEC’s website at www.sec.gov.
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Translate Bio
Translate Bio is a clinical-stage mRNA
therapeutics company developing a new class of potentially
transformative medicines to treat diseases caused by protein or gene
dysfunction.
Forward-Looking Statements
Statements in this press release
about future expectations, plans and prospects, as well as any other
statements regarding matters that are not historical facts, may
constitute “forward-looking statements” within the meaning of The
Private Securities Litigation Reform Act of 1995. These statements
include, but are not limited to, statements relating to the implications
of preliminary clinical data, the anticipated grant of an over-allotment
option and the expected initial public offering price. The words
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,”
“target,” “will,” “would” and similar expressions are intended to
identify forward-looking statements, although not all forward-looking
statements contain these identifying words. Actual results may differ
materially from those indicated by such forward-looking statements as a
result of various important factors, including: the uncertainties
related to market conditions and the completion of the public offering
on the anticipated terms or at all, and other factors discussed in the
“Risk Factors” section of the preliminary prospectus filed with the
Securities and Exchange Commission. Any forward-looking statements
contained in this press release speak only as of the date hereof, and
Translate Bio specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
